|Mr. Timothy P. Walbert||Chairman, Pres & CEO||N/A||N/A||1967|
|Mr. Paul W. Hoelscher||Exec. VP & CFO||N/A||N/A||1965|
|Mr. Barry J. Moze||Exec. VP & Chief Admin. Officer||977.54k||N/A||1954|
|Ms. Irina Konstantinovsky||Exec. VP & Chief HR Officer||514.53k||N/A||1970|
|Mr. Miles W. McHugh||Chief Accounting Officer & Sr. VP||N/A||N/A||1965|
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; and Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Horizon Pharma Public Limited Company’s ISS Governance QualityScore as of November 1, 2018 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 3.